🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 7 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 20/08/1992 | 5,13 | 5,13 | 4,75 | 4,88 | +0,00% | 7,32% | 27.800 |
| 19/08/1992 | 5,00 | 5,13 | 4,88 | 4,88 | +0,00% | 5,00% | 51.400 |
| 18/08/1992 | 5,25 | 5,25 | 4,88 | 4,88 | -3,70% | 7,14% | 60.400 |
| 17/08/1992 | 5,25 | 5,25 | 5,00 | 5,06 | -1,22% | 4,76% | 14.200 |
| 14/08/1992 | 5,25 | 5,25 | 5,00 | 5,13 | +2,50% | 4,76% | 85.400 |
| 13/08/1992 | 4,50 | 5,25 | 4,50 | 5,00 | +9,59% | 16,67% | 104.200 |
| 12/08/1992 | 4,50 | 4,75 | 4,38 | 4,56 | +7,35% | 8,33% | 51.200 |
| 11/08/1992 | 4,25 | 4,50 | 4,25 | 4,25 | +0,00% | 5,88% | 9.200 |
| 10/08/1992 | 4,50 | 4,50 | 4,25 | 4,25 | -5,56% | 5,56% | 7.600 |
| 07/08/1992 | 4,13 | 4,50 | 4,13 | 4,50 | +9,09% | 9,09% | 51.400 |
| 06/08/1992 | 4,38 | 4,38 | 4,13 | 4,13 | -5,71% | 5,71% | 19.400 |
| 05/08/1992 | 4,25 | 4,38 | 4,00 | 4,38 | +6,06% | 8,82% | 171.200 |
| 04/08/1992 | 4,00 | 4,25 | 4,00 | 4,13 | -2,94% | 6,25% | 120.800 |
| 03/08/1992 | 4,25 | 4,25 | 4,00 | 4,25 | +0,00% | 5,88% | 2.400 |
| 31/07/1992 | 4,25 | 4,25 | 4,00 | 4,25 | +6,25% | 5,88% | 51.800 |
| 30/07/1992 | 4,25 | 4,25 | 4,00 | 4,00 | -5,88% | 5,88% | 4.800 |
| 29/07/1992 | 4,25 | 4,25 | 4,13 | 4,25 | +0,00% | 2,94% | 29.800 |
| 28/07/1992 | 4,25 | 4,25 | 4,06 | 4,25 | +3,03% | 4,41% | 437.200 |
| 27/07/1992 | 4,38 | 4,38 | 4,13 | 4,13 | -5,71% | 5,71% | 69.400 |
| 24/07/1992 | 4,38 | 4,38 | 4,13 | 4,38 | +0,00% | 5,71% | 105.200 |
| 23/07/1992 | 3,88 | 4,63 | 3,81 | 4,38 | +16,67% | 20,97% | 354.800 |
| 22/07/1992 | 3,88 | 3,88 | 3,63 | 3,75 | -3,23% | 6,45% | 71.400 |
| 21/07/1992 | 3,56 | 3,88 | 3,56 | 3,88 | +5,08% | 8,77% | 336.600 |
| 20/07/1992 | 3,50 | 3,75 | 3,50 | 3,69 | -1,67% | 7,14% | 80.200 |
| 17/07/1992 | 3,63 | 3,75 | 3,56 | 3,75 | +1,69% | 5,17% | 79.200 |
| 16/07/1992 | 3,50 | 3,75 | 3,50 | 3,69 | +1,72% | 7,14% | 86.800 |
| 15/07/1992 | 3,75 | 3,75 | 3,50 | 3,63 | -3,33% | 6,67% | 123.800 |
| 14/07/1992 | 3,75 | 3,75 | 3,50 | 3,75 | +5,26% | 6,67% | 9.000 |
| 13/07/1992 | 3,75 | 3,75 | 3,50 | 3,56 | -3,39% | 6,67% | 68.200 |
| 10/07/1992 | 3,63 | 3,75 | 3,50 | 3,69 | +1,72% | 6,90% | 167.200 |